pteridines has been researched along with Recrudescence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berdel, WE; Bug, G; Döhner, H; Fleischer, F; Fritsch, H; Garin-Chesa, P; Krämer, A; Krauter, J; Lübbert, M; Müller-Tidow, C; Munzert, G; Nachbaur, D; Ottmann, OG; Taube, T; Valent, P | 1 |
| Awad, MM; Bonomi, PD; Bradford, DS; Chu, QS; Eaton, KD; Ellison, DM; Fritsch, H; Gandhi, L; Govindan, R; Johnson, BE; Munzert, G; Socinski, MA; Stephenson, JJ | 1 |
2 trial(s) available for pteridines and Recrudescence
| Article | Year |
|---|---|
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Recurrence; Treatment Outcome | 2013 |
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Topics: Administration, Intravenous; Adult; Aged; Cell Cycle Proteins; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Recurrence; Small Cell Lung Carcinoma; Smoking; Treatment Failure; Treatment Outcome | 2017 |